I-Skin Rash nezinye izibonakaliso ngenxa yeTarceva (Erlotinib)
Uma uke wabhekana nokushisa okufana ne-acne, isikhumba esomile, ukuhlahlela, nokuguquka kwe-nail ngesikhathi uthatha i-Tarceva (erlotinib) awusiye wedwa. Kubantu abathile abanomdlavuza wamaphaphu, ukwelashwa okuhlosiwe uTarceva (erlotinib,) kanye nezinye izidakamizwa ze-epidermal growth receptor (EGFR) inhibitors, baye bazibuza izidakamizwa ngendlela eya kubantu abanomdlavuza wamaphaphu omuhle we-EGFR. Lezi zokwelapha ziye zathuthukisa izinga lokuphila ngenkathi ziphila nomdlavuza, zisinda, futhi zivame ukuba nemiphumela emibi kunezindlela zemithi ejwayelekile.
Omunye umphumela wecala, noma kunjalo, uthola ukunakwa okuningi: izinkinga zesikhumba
Iningi labantu abasebenzisa le mithi iTarceva (kanye nezinye i-EGFR inhibitors) zihlakulela ukushona, futhi ngokuthakazelisayo, ukubonakala kwe-rash kuye kwahambisana nokuphendula kumuthi. Njengoba le mithi ivame ukuthathwa isikhathi eside, kubalulekile ukuxoxa ngokuphathwa kwanoma yiziphi izimpawu ezingathandeki nge-oncologist yakho.
(Uma unomdlavuza wamaphaphu, ikakhulukazi i-lung adenocarcinoma, qiniseka ukuthi udokotela wakho wenze ukuhlolwa kofuzo (ukufometha kwamangqamuzana) kwesisu sakho.)
Yiziphi Izinkinga Zesikhumba Ezivamile NeTarceva (Erlotinib)?
Izinkinga zesikhumba evamile abantu ababhekana nazo kuTarceva (nezinye izifo ezikhulayo ze-epidermal factor inhibitors) zifaka:
- I-acne type rash (i-rash acneiform) - Lokhu kuqhuma kuvame ukufana ne-acne ebonwa entsheni. Ngokuvamile kuhilela ubuso, indawo ngemuva kwezindlebe, intamo, isiqu esingaphezulu ngephethini enemihlobiso enguV, kanye ne-scalp. Ngokuvamile ngokuvamile kuthinta emuva ephansi, isisu, izintanjane, nemiphetho ephezulu nangaphansi. Ukuqhuma akuveli ezintendeni zezandla noma izinyawo. Isimiso sezinkondlo zemvelo singase sidideke uma ufunda ulwazi ngalokhu kuqhuma, kodwa izincazelo ezimbalwa ezilula zingasiza. I-papule ivele isho ukuthi i-bump esikhumbeni. I-pustule isho i-bump ebukeka igcwele i-pus noma idwengula. Igama elithi follicular lisho ukuthi izilonda zesikhumba ziseduze noma ezinyangeni zezinwele.
- Isikhumba esomile (xeroderma)
- I-itching (pruritis)
- Ubuqotho obuzungeze isisekelo somunwe noma i-toenail (paronychia)
Yeka ukuthi i-Rash ijwayelekile kangakanani?
Iningi labantu elashwe ngemithi efana neTarceva inesikhumba esincane noma esilinganiselwe, ikakhulukazi uhlobo lokuqhaqha okufana ne-acne, nesikhumba esomile.
Impact yezinkinga zesikhumba zeTarceva
Izinkinga zesikhumba kwi-inhibitor ye-epidermal growth factor receptor inhibitors zingathinta kakhulu kokubili izinga lomzimba kanye nengokomzwelo yokuphila kubantu abathola le mithi.
Ucwaningo olulodwa luthole ukuthi le nemiphumela emibi yathinteka impilo enempilo, esebenzayo, engokomzwelo, kanye nenhlalakahle yeziguli ezidakamizwa. Izikhalazo ezivame kakhulu ziphathelene nezimpawu zomzimba, kuhlanganise nobuhlungu, ukuzwa okuvuthayo nokuzwela.
I-Rash ivela nini futhi ihlala isikhathi eside kangakanani?
Ukuvuthwa kwezikhumba eTarceva kuvame ukuqala amasonto angu-1 kuya kwangu-2 emva kokuqala ukwelashwa, kusezinsukwini zabo ezimbi kakhulu kuya kwezingu-3 emva kokuba ukwelashwa sekuqalile, futhi kungase kube kancane kancane ukuxazulula noma ukunyamalala ngokuphelele ezinyangeni ezimbili kuya kwezintathu ezilandelayo. Ukwazi ukuthi ukuqhuma okuvame ukuthuthukisa ngokuhamba kwesikhathi kuye kwasiza abanye abantu ukuba babhekane nalezi zimpawu.
Ingabe i-Rash isho ukuthi i-Tarceva iyasebenza kangcono yini?
Ucwaningo lubonisa ukuthi abantu abahlakulela ukukhwabanisa izidakamizwa banesilinganiso sempendulo engcono futhi basinda kangcono. Ngenxa yalokhu, futhi ngenxa yokuthi izidakamizwa zivame ukuthathwa isikhathi eside, kubaluleke kakhulu ukuba kusebenze ekuphatheni izimpawu zokukhwabanisa.
Izinkinga zesikhumba ezihlobene nezinye izindlela zokwelashwa ezifana ne-chemotherapy kanye nokwelashwa kwemisebe kungase kube khona kanye nalabo abavela eTarceva futhi kufanele baqondiswe ngokucophelela nge-oncologist yakho.
Ubukhulu beRash
Izinhlayiya ze-Acne ngenxa yeTarceva zivame ukwehla zibe yizigaba ezintathu:
- Ubumnene: I-Tarceva elula ichazwa njengelinye elingenalo isilonda (izindawo ezivulekile) ukukhala (ukugeleza) noma ukutheleleka. Abantu ngokuvamile banezimpawu ezincane kuphela futhi akuphazamisi imisebenzi evamile yokuphila.
- Okulinganiselwe: Ukuqhuma okulinganiselwe kwe-Tarceva kungenziwa endaweni noma kujwayelekile. Ngokuvamile akuzona izilonda, ukukhala noma ukutheleleka. Kungenzeka kube khona izimpawu zokubamba kanye nokubonisa ububele, kodwa kukhona ukuphazanyiswa okuncane kakhulu ngemisebenzi yokuphila.
- Okukhulu: I-Tarceva enzima kakhulu ijwayele ukuvuthwa (ukumboza ubuso, isifuba esingenhla nangaphezulu) futhi kuvame ukuhambisana nezibonakaliso ezinzima zokubamba nokuthula. Lithinta kakhulu izinga lempilo. Kukhona ukulonda (izilonda ezivulekile) ukukhala (amanzi) kanye nezibonakaliso zokutheleleka kwesikhumba okufana nokubomvu, ukuphuza okuphuzi noma okwesibhakabhaka kanye nomkhuhlane.
I-Skin Rashes Isuka Kanjani I-Tarceva?
Ukushona kwakho kuzophathwa kanjani kuzoxhomeka ekubambeni kokushayeka, kanye nezintandokazi zakho. Ngisho noma ukuqhuma kufana nemfucumfucu, akusiyo ukuqhuma kwama-acne, futhi ngeke kuphendule eziningi zokwelashwa kwama-acne.
I-Tarceva (Erlotinib) I-Rash Prevention ne-Daily Care
Isinyathelo sokuqala ekulawuleni ukuvimbela: Amasu okuzivikela ahlanganisa ukugcina isikhumba sihlanzekile, ukugwema ukushisa kwelanga, nokusebenzisa ama-moisturizers ukuze ugcine isikhumba sakho sihlanjululwe. Ukubheja okungcono kakhulu ekugwemeni ukushisa kwelanga ukugwema ukukhanya kwelanga phakathi kwemini, besebenzisa izingubo zokuzivikela, njengama-sunscreen futhi ikakhulukazi ukushisa kwelanga kungenza ukuqhuma kwe-Tarceva kudonsa kakhulu. Ukubandakanya ukukhwabanisa ngemikhiqizo ye-vaseline nakho kungakwandisa ubuhlungu bezinwele ze-hair and infringed the rash. (Hlola lezi zeluleko ngokuphepha kwelanga ngesikhathi ukwelashwa komdlavuza .)
Kubalulekile ukuqaphela ukuthi ukwelashwa kwesifo esisodwa okuhlobene neTarceva kungase kube nzima nakakhulu kwesinye isibonakaliso futhi kuhloswe. Isibonelo, ama-moisturizers angasiza ngokumelela nokubamba kodwa kuphazamisa ukuqhuma kohlobo lwe-acne.
I-Tarceva (i-Erlotinib) i-Rash Treatments
Ukwelashwa kwe-Tarceva ukuhlaselwa kuxhomeke ekutheni ngabe ukushaywa komzimba kutholakale noma cha, futhi kungabandakanya kokubili ukuphatha ukuqhuma, noma ukulungisa umthamo. Lezi zikhetho zingabandakanya:
Izinhlobo zokwelashwa:
- Imithi yokwelapha: Ama-antibiotic asuselwa e-clindamycin kanye / noma i-hydrocortisone yama-topical ngokuvamile asetshenziselwa ukukhishwa kwe-acne-type Tarceva. Izifundo zibheke ekusebenziseni u-vitamin K cream, kanye ne-epidermal ukukhula kwamafutha okugcoba, okubili bobabili ababonise isithembiso ekuvivinyweni kokwelashwa. Kubalulekile ukuthi uphinde uqaphele ukuthi nakuba ukuqhuma kufana nemifino, akusikho, futhi ukwelashwa okuningi kwe-acne ngeke kusize ngokushona.
- Ukwelashwa komlomo: Uma ukwelashwa kwama-topical akulwane, ukwelapha ngomlomo nge-anti-antibiotics ehlukene ye-tetracycline kungasetshenziswa. Ucwaningo lubuye lubheke ekusetshenzisweni kokwelapha ngomlomo, njengemlomo we-minocycline njengokwelashwa kwe-prophylactic; iqalile ngaphambi kokuqhuma kwenzeka.
Ukunakekelwa kwe-Rash Alone: Uma izimpawu zifaka ukuqhuma okubomvu kuphela ngaphandle kwezibonakaliso zokutheleleka, iphathwa nge-steroids ye-topical, i-hydroxyortortone engama-1%, noma i-2.5% uma ukuqhuma kunzima. Kulesi simo, kukhona ubomvu kodwa akukho amhlophe amhlophe angabonisa ukuthi ukutheleleka kukhona.
Ukwelashwa Kwe-Rash Ethelelekile: Uma ukukhwabanisa kwe-Tarceva kunzima ngokutheleleka kokubili kwebhaktheriya akukhona kuphela ukubomvu kodwa ngokuvamile kubonisa ukuthi kukhona ukutheleleka okunjengamhlophe. Uma kunjalo, ukwelashwa kufanele kufaka kokubili ama-antibiotic omlomo (tetracyclines) kanye nejelisi le-clindamycin yama-topical.
Ukulungiswa kwesilinganiso : Amaphesenti angama-10 abantu ahlakulela ukuqubuka okudinga ukuguqulwa kwemithi. Isilinganiso "esivamile" seTarceva singama 150 mg nsuku zonke. I-oncologist yakho ingase icabange ukunciphisa leli dose ku-100 mg noma ngisho no-50 mg nsuku zonke. Lokhu kungethusa, ikakhulukazi uma imithi ikusebenzela kahle. Kungasiza ukuthi uqaphele ukuthi ngisho namanani aphansi kakhulu aseTarceva, aphansi ngo-25 mg nsuku zonke, aye esebenza kahle ekuphatheni abanye abantu abanomdlavuza wamaphaphu.
> Imithombo:
> Society of American of Clinical Oncology. Cancer.net Ukusabela Kwesikhumba Emitholampilo Ebhekiswe. Ifinyelele ngo-05/2016. http://www.cancer.net/navigating-cancer-care/side-effects/skin-reactions-targeted-therapy-and-immunotherapy
> Burotto, M., Manasanch, E., Wilkerson, J., noT. Fojo. I-Gefitinib ne-erlotinib emdlashini we-metapatic ongasona omncane wesifo samaphaphu: ukuhlaziywa kwe-meta-toxicity kanye nokuphumelela kokuhlolwa kwamakhambi okungahleliwe. Oncologist . 2015. 20 (4): 400-10.
> Califano, R. et al. I-Consensus Consensus mayelana Nokuphathwa Kwezenzakalo Ezimbi Ezivela EGFR iTrosros Kinase Inhibitors e-UK. Izidakamizwa . 2015. 75 (12): 1335-48.
> Fabbrocini, G., Panariello, L., Caro, G., no-S. Cacciapuoti. I-Acneiform Rash Ekhuthazwa yi-EGFR Inhibitors: Ukubukezwa Kwezincwadi Nezingqinamba Ezintsha .. Izinkinga Zokukhubazeka Kwesikhumba . 2015. 1: 31-37.
> Hwang, I. et al. Isivivinyo sesiGaba II se-epidermal ukukhula kwamafutha okugcoba iziguli ezinezikhumba ezihlobene ne-Erlotinib. Ukondla Ukusekela Ekhanda . 2015 Jun 4. (Epub ngaphambi kokuphrinta).
> Kiyohara, Y., Yamazaki, N., no A. Kishi. Izidakamizwa ezihlobene nezikhumba ze-Erlotinib: amasu ekwelashwa kwiziguli ezine-metastatic non-small cell cell lung cancer. Umagazini we-American Academy of Dermatology . 2013. 69 (3): 463-72.
> Ocvirk, J., Heeger, S., McCloud, P., no R. Hofheinz. Ukubuyekezwa kokukhethwa kokwelashwa kokukhishwa kwesikhumba okubangelwa izindlela zokwelapha ezibhekiswe ku-EGFR: Ubufakazi obuvela ezivivinyweni zomtholampilo ezingahleliwe kanye nokuhlaziywa kwemeta. I-Radiology ne-Oncology . 2013. 47 (2): 166-75.
> Passaro, A. et al. ukuphathwa kwezidakamizwa ezingenayo i-nonhematologic ezihambisana ne-EGFR-TKI ehlukene ku-NSCLC ehamba phambili: ukuhlaziywa kokuqhathanisa. Cancer Cancer Clinic . 2014. 15 (4): 307-12.
> Shinohara, A. et al. Ukusebenza kokwelashwa kwe-minocycline ye-prophylactic ye-toxicity yesikhumba okubangelwa i-erlotinib plus gemcitabine kwiziguli ezine-cancer ephakeme ye-pancreatic: isifundo esiphendukayo. Journal American of Dermatology Clinic . 2015. 16 (3): 221-9.
> Szejiniuk, W., McCullock, T., no-O. Roe. Izindlela eziphumelelayo ze-ultra-low of erlotinib ezigulini ezine-EGFR ezithinta ukushintshashintsha. Imibiko ye-BMJ Case . 2014. I-Doi: 10.1136 / bcr-2014-204809.